A

Apontis Pharma AG
XETRA:APPH

Watchlist Manager
Apontis Pharma AG
XETRA:APPH
Watchlist
Price: 9.64 EUR -1.43% Market Closed
Market Cap: 80.3m EUR
Have any thoughts about
Apontis Pharma AG?
Write Note

Apontis Pharma AG
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Apontis Pharma AG
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
A
Apontis Pharma AG
XETRA:APPH
Long-Term Debt
€0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ATAI Life Sciences NV
NASDAQ:ATAI
Long-Term Debt
$17.9m
CAGR 3-Years
108%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bayer AG
XETRA:BAYN
Long-Term Debt
€36.7B
CAGR 3-Years
0%
CAGR 5-Years
-1%
CAGR 10-Years
12%
Merck KGaA
XETRA:MRK
Long-Term Debt
€7.9B
CAGR 3-Years
-1%
CAGR 5-Years
-2%
CAGR 10-Years
14%
Dermapharm Holding SE
XETRA:DMP
Long-Term Debt
€904.6m
CAGR 3-Years
16%
CAGR 5-Years
15%
CAGR 10-Years
N/A
PharmaSGP Holding SE
XETRA:PSG
Long-Term Debt
€65.8m
CAGR 3-Years
669%
CAGR 5-Years
205%
CAGR 10-Years
N/A
No Stocks Found

Apontis Pharma AG
Glance View

Market Cap
80.3m EUR
Industry
Pharmaceuticals

APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.

APPH Intrinsic Value
15.03 EUR
Undervaluation 36%
Intrinsic Value
Price
A

See Also

What is Apontis Pharma AG's Long-Term Debt?
Long-Term Debt
0 EUR

Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Long-Term Debt amounts to 0 EUR.

Back to Top